CYP19A1 and breast cancer: In a single-center, cross-sectional study of 556 postmenopausal women with early-stage breast cancer receiving AI treatment the proportion of vertebral fractures in the aromatase inhibitor-treated group was 20.0 % in patients with low FBM versus 33.3 % in patients with high FBM (p = 0.04).